[Symptoms of prostate cancer that required treatment in the terminal stage for two years].

We conducted a study of the symptoms of prostate cancer that required medical treatment in terminal patients intermittently hospitalized over a period of two years. We examined the medical records of 54 out of 55 patients who died of prostate cancer between January 2000 and December 2008. The period from the initial visit to death was between 6 and 179 months (median : 48 months). The frequency of hospitalization per patient within two years before death was between 0 and 12 times (median : 3 times). The leading causes of hospitalization (a total of 191 times) were pain (44 times), a poor physical condition (30 times), hematuria (23 times), cancer treatment (22 times), anemia (18 times), and urinary retention (12 times). Thirty-two cases required the use of opioids (0.5 to 25 months before death, median : 5 months), 25 cases required blood transfusion (0.5 to 24, median : 5 months), 17 cases required long-term catheterization (0.5 to 16, median : 4 months), 10 cases required external beam radiation (2 to 25, median : 15 months), 6 cases required percutaneous nephrostomy (0.5 to 7, median : 2 months), three cases required transurethral resection of the prostate (3 to 23, median : 23 months), and two cases required fracture fixation (5 to 6 months before death). Since urologists are in charge of patients from their initial visit to the terminal stage, they are required not only to immediately address, or prevent if possible, these symptoms appearing in the terminal stage, but also to help enhance the quality of life of patients by providing palliative care based on expert knowledge.

[1]  T. O'brien,et al.  The Importance of Palliative Care in Urology , 2008, Urologia Internationalis.

[2]  N. Clarke,et al.  Complications arising in the final year of life in men dying from advanced prostate cancer. , 2007, Journal of palliative medicine.

[3]  D. Petrylak The current role of chemotherapy in metastatic hormone-refractory prostate cancer. , 2005, Urology.

[4]  C. Amling,et al.  Palliative transurethral prostate resection for bladder outlet obstruction in patients with locally advanced prostate cancer. , 2004, The Journal of urology.

[5]  F. Saad,et al.  A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. , 2002, Journal of the National Cancer Institute.

[6]  D. Lubeck,et al.  Quality of life before death for men with prostate cancer: results from the CaPSURE database. , 2001, The Journal of urology.

[7]  D. Giannarelli,et al.  Radiation therapy in the management of symptomatic bone metastases: the effect of total dose and histology on pain relief and response duration. , 1998, International journal of radiation oncology, biology, physics.

[8]  D P Dearnaley,et al.  A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. , 1994, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[9]  D. King,et al.  The role of percutaneous nephrostomy in malignant urinary tract obstruction. , 1993, Clinical radiology.

[10]  W. DeWolf,et al.  High failure rate of indwelling ureteral stents in patients with extrinsic obstruction: experience at 2 institutions. , 1989, The Journal of urology.

[11]  R. Weiss,et al.  Radiation therapy for local palliative treatment of prostatic cancer. , 1972, The Journal of urology.